IN8BIO, Inc.
INAB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001740279
No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding IN8BIO, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 19 | 22 | +3 |
| Shares | 980.3K | 3.23M | +2.25M (+229.3%) |
| Value | $2.13M | $7.45M | +$5.32M (+250.3%) |
New holders (7)
Institutions that held IN8BIO, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| 683 Capital Management, LLC | 724,637 | $1.70M | 0.14% |
| Texas Capital Bank Wealth Management Services Inc | 23,750 | $55.6K | 0.00% |
| Captrust Financial Advisors | 18,295 | $42.8K | 0.00% |
| Northern Trust Corp | 17,400 | $40.7K | 0.00% |
| HRT Financial LP | 14,913 | $34.0K | 0.00% |
| Jones Financial Companies LLLP | 1,228 | $2.87K | 0.00% |
| Morgan Stanley | 34 | $80 | 0.00% |
Sold out (4)
Institutions that held IN8BIO, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Jane Street Group, LLC | 26,182 | $56.8K |
| Citadel Advisors LLC | 24,728 | $53.7K |
| DRW Securities, LLC | 18,300 | $39.7K |
| Citigroup Inc | 49 | $106 |